The long-awaited and much-leaked European Commission's pharmaceutical legislation was finally published last week. Most of the new proposals have received a hearty thumbs down from the industry due to concerns that the proposals will limit intellectual property. The EU may be one regulated market but it remains a complex patchwork of national healthcare systems, clinical communities and currencies which do not lend themselves, nor seek to be a homogeneous whole. From a UK perspective, the UK has increased its attractiveness as a market simply by standing still, and I have to admit I didn’t think that it would be direct moves by the EU that would make the case for Brexit. Read more on LIFTS, VPAS and HSBC SVB UK...
